|Bid||25.73 x 0|
|Ask||25.67 x 0|
|Day's range||22.24 - 29.70|
|52-week range||9.39 - 29.99|
|Beta (3Y monthly)||0.73|
|PE ratio (TTM)||78.96|
|Earnings date||30 Aug 2016 - 3 Sep 2016|
|Forward dividend & yield||0.02 (0.07%)|
|1y target est||32.70|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR.
MELBOURNE, Australia and SINGAPORE, Dec. 19, 2018 -- SUMMARY Phase II study in vitiligo, a treatment-resistant disease1n=21, patients of Asian ethnicity, darker skin.
The direct benefit for Clinuvel Pharmaceuticals Limited (ASX:CUV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...